INTRODUCTION
Acute coronary syndrome (ACS), a category that includes unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI), is a significant global health problem and a leading cause of death related to cardiovascular diseases (1) .
There is a strong association between ACS and the disruption of vulnerable atherosclerotic plaques and subsequent thrombus formation. The rupture or erosion of these plaques initiates the thrombotic process by exposing the prothrombotic content of necrotic cores to circulating thrombocytes (2, 3) . Thereafter, the activation of both circulating platelets and the coagulation cascade results in thrombin formation (4) .
Prothrombin time (PT) or international normalized ratio (INR) is accepted as a reliable marker of coagulation abnormalities. It is regulated by various coagulation factors synthesized in the liver and is used to monitor vitamin-K-dependent anticoagulation therapy. PT may also reflect hepatic dysfunction and coagulation abnormalities such as disseminated intravascular coagulation (DIC). Prolonged PT has been reported to be associated with poor clinical outcomes in critically ill patients (5, 6) . Similarly, it has recently been shown that an increase in PT is associated with high mortality in patients with both heart failure and acute pulmonary embolism (7, 8) .
To the best of our knowledge, there are no data about whether initial PT at presentation will affect the long-term prognosis of ACS patients. Thus, this study evaluated the association of initial PT with all-cause mortality in patients with ACS treated with percutaneous coronary intervention (PCI) who had not received anticoagulant therapy.
PATIENTS and METHODS

Study Population
Conducted from January 2008 to July 2015, this retrospective study included a total of 1.193 consecutive patients with ACS treated with PCI. To be enrolled in the study, patients had to have clinical and angiography-proven ACS and baseline PT measurements. Fifty nine patients with incomplete data, two with a history of liver cirrhosis, and thirty two who had received anticoagulant therapy (vitamin-K antagonists, direct thrombin inhibitors, direct factor Xa inhibitors, or enoxaparin) were excluded from the analysis. Consequently, the final study population consisted of 1.100 patients ( Figure 1 ). The cut-off points of PT were determined according to the reference range of the reagent RecombiPlasTin (manufacturer-datasheet ACL TOP: 9.4 -12.5 seconds) and reference values used in previous studies (PT ≥ 14 sec) (9) . Based on the PT cut-off points, the study population was divided into a high-PT group (PT ≥ 14 sec, n= 50), intermediate-PT group (12.5 < PT < 14 sec, n= 169), and low-PT group ( PT ≤ 12.5 sec n= 881). The local ethics committee approved the study (the number of the local ethics committee: 322). The study conforms to the Declaration of Helsinki.
Blood Sampling and PT Measurement
All the measurements of PT, activated partial thromboplastin time (aPTT), and INR were performed at the presentation of the patients prior to the initiation of anticoagulant therapy and coronary angiography. The blood-collection tubes contained 3.2% sodium citrate (0.5 mL citrate, 4.5 mL blood) for INR, PT, and aPTT measurements. Samples were immediately centrifuged for routine testing, and the analysis was performed within 1 h after sampling. The reagent HemosIL RecombiPlasTin 2G (Instrumentation Laboratory, Bedford, MA, USA) was used to measure INR. The reagent HemosIL SynthASil (Instrumentation Laboratory, Bedford, MA, USA) was used to perform the measurement of a PTT. Complete blood count was determined via an Abbott Cell-Dyn 3700 autoanalyzer using commercial assay kits (Abbott Diagnostic, CA, US). Siemens Healthcare Diagnostic Products kits and calibrators (Marburg, Germany) was used to perform the biochemical measurements.
Echocardiographic Analysis
Echocardiographic examinations were performed for all the patients. The left ventricular ejection fraction (LVEF) was calculated after measuring the end-diastolic and end-systolic left ventricle (LV) volumes in the apical four-chamber and twochamber views using the modified Simpson's method.
Treatment
All the coronary angiography and PCI procedures were performed via the transfemoral route by experienced interventional cardiologists. Both the UA and NSTEMI patients underwent coronary angiography with subsequent PCI within the first 48 h. Primary PCI for STEMI was performed according to the current guidelines (10) . The diagnosis of CAD was confirmed by coronary angiography in all the patients and consisted of documentation of a significant disease (defined as coronary stenosis ≥ 50% luminal narrowing in at least one of the major coronary arteries) or an infarct-related artery. The angiographic data of the patients were evaluated from catheter laboratory records. All the patients were treated according to good clinical küre sayısı, total bilirubin seviyeleri ve Killip sınıfını içeren çok değişkenli bir modele PZ'nin eklenmesi %26.7'lik bir net yeniden sınıflandırma iyileşmesi (p< 0.001) ve 0.022'lik total bir ayrımcılık iyileşmesi (p= 0.001) sağladı. practice and the current guidelines (10, 11) . The type of stent and the use of thrombectomy devices, predilation, poststenting adjunctive balloon inflation, intravascular ultrasound, intra-aortic balloon counterpulsation, or glycoprotein IIb/IIIa inhibitors were all left to the operators' discretion. Dual antiplatelet therapy, beta-blockers, angiotensin-converting enzyme inhibitors, and statins were administered according to the European Society of Cardiology guidelines (10, 11) .
Definition
According to the criteria of the universal definition of myocardial infarction, the diagnosis was established in the presence of an increasing/decreasing pattern in cardiac troponin I values, with at least one measurement above the 99 th percentile together with evidence of myocardial ischemia (12) . Additionally, myocardial infarction was classified as STEMI or NSTEMI according to current guidelines (10, 11) . STEMI involves the new-onset angina of at least Canadian Cardiovascular Society (CCS) class III severity, or (c) recent acceleration of angina reflected by an increase in severity of at least one CCS class to at least CCS class III (11) . Cardiovascular risk factors (arterial hypertension, diabetes, hypercholesterolemia, and smoking) were defined according to the accepted criteria.
The primary study end point was defined as the occurrence of all-cause total mortality during the median follow-up of 30.5 months. In addition, cardiac death, myocardial reinfarction, stroke/ transient ischemic attack (TIA), target-vessel revascularization (TVR), and heart failure admission were assessed. Reinfarction was defined according to the third universal definition of MI (11) . TVR was defined as any revascularization procedure, including bypass surgery, involving the initially treated artery. Stroke/ TIA was defined as an acute neurological deficit accompanied by brain imaging compatible with a recent ischemic or hemorrhagic event. Bleeding events were defined using the criteria of the Academic Research Consortium definition (13) .
Follow-up
By design, although the study represents a retrospective analysis, monitoring and event data were obtained from a prospective order. The patients were followed for clinical events such as deaths, MI, stroke, and heart failure during the median follow-up of 30.5 months. The follow-up data were obtained from hospital records or by interviewing (in person or by telephone) patients, their families, or their personal physicians.
Statistical Analysis
Continuous variables were presented as means ± SD or medians with inter-quartile ranges (IQR), whereas categorical variables were described as numbers and percentages. The differences between the two groups were compared using the chi-square test (or Fisher's exact) for categorical variables and with analysis of variances (ANOVA) or Kruskal-Wallis test for continuous variables, as appropriate. The relationship between PT and the other demographic/biochemical parameters was assessed with Pearson's correlation analysis. The predictive values of a multivariable model and a combination of PT and a multivariable model were estimated by comparing the areas under the receivers operating characteristic (ROC) curve.
DeLong's test was used to compare the AUC from each of models, which were analyzed by use of Analyse-it software program (14) . Moreover, the increased discriminative value after the addition of PT to a multivariable model was also estimated using the net reclassification improvement (NRI) and Integrated Discrimination Improvement (15) . The cumulative survival curves for total mortality were estimated with Kaplan-Meier plots. A log-rank test was used to analyze the significant differences in survival curves. A multivariate Cox regression analysis was performed to identify independent predictors for the primary end point. Factors entered into the multivariate model comprised those with p-values < 0.1 from the univariate analysis and variables with known prognostic value. Two-sided p-values < 0.05 were considered statistically significant. The statistical tests were performed with SPSS version 16 (SPSS Inc., Chicago, IL, USA). Table 1 lists the baseline characteristics of the study patients. Overall the mean age was 62 ± 12 years and there were 26% females. The median follow-up period was 30.5 months. The patients in the high-PT group were older than the patients in the other groups. Compared with the low-PT group, the history of heart failure and higher Killip class were more frequent both in the intermediate and high-PT groups. On the other hand, the use of angiotensin-converting enzyme inhibitors and beta-blockers were lower both in the low and high-PT groups than the low-PT group ( Table 1) . The major bleeding rates were similar between groups. Table 2 shows the laboratory variables of the groups. The LVEF was significantly lower both in the high and intermediate-PT group than in the other groups (p< 0.001). Both the high-PT and intermediate-PT group had higher levels of white blood count (WBC) than the low-PT group did.
RESULTS
Baseline Characteristics
Laboratory Findings
In the correlation analysis, PT was inversely and weakly correlated with LVEF (r= −0.23, p< 0.001), hemoglobin levels (r= -0.10, p< 0.001), but positively correlated with age (r= 0.14, < 0.001), WBC count (r= 0.11, p< 0.001), creatinine (r= 0.11, p= 0.001), total bilirubin (r= 0.27, p< 0.001), and alanine aminotransferase (ALT) levels (r= 0.08, p= 0.013). Table 1 ). Furthermore, Cardiac-cause mortality was higher in the high-PT group compared with the others (Table 1) . Similarly, 30-day mortality rate was 3% in the low-PT group, 8% in the intermediate-PT group, and 20% in high-PT group.
PT and Clinical Outcomes
Hospitalization for heart failure was significantly higher in the high-PT group. TVR, myocardial reinfarction and stroke/TIA rates were comparable in the groups.
In the multivariate Cox regression analysis, high-PT (HR: 2.648, 95% CI:1.590-4.410, p< 0.001), age, Killip class, LVEF, total bilirubin, serum creatinine, hemoglobin levels, WBC, histories of DM and stroke/TIA were independent predictors of long-term mortality ( Table 3) .
For long-term mortality, the AUC of a multivariable model that included age, WBC, creatinine, total bilirubin, hemoglobin, LVEF, Killip class, histories of DM and stroke/TIA was 0.820 (95% CI: 0.785-0.854, p< 0.001). When PT was added to a multivariable model, the AUC was 0.833 (95% CI: 0.799-0.867, difference p= 0.0398, Figure 2 ). Moreover, the addition of PT to a multivariable model was associated with a significant NRI estimated at 26.7% (p< 0.001) and an integrated discrimination improvement of 0.022 (p= 0.001) ( Table 4 ). Figure 3 shows the Kaplan-Meier survival curves. In addition, we performed a landmark analysis in these patients. Even after performing a landmark analysis at day-30 after the diagnosis of ACS, the high-PT group had a lower survival rate both during the first 30-days and after 30-days ( Figures 4A, and B) . 
DISCUSSION
This is the first study to investigate the association of admission PT level in the absence of previous anticoagulant therapy with all-cause total mortality in ACS patients who were treated with PCI. We observed that prolonged PT was associated with increased all-cause mortality in those patients who did not receive anticoagulant therapy during the median follow-up of 30.5 months.
The increased PT in ACS patients may be due to several mechanisms. The activation of inflammatory and coagulation pathways plays an important role in the pathogenesis of vascular diseases. There is growing evidence of cross-talk relation between these two systems; that is, one can trigger the other (16) . Inflammation and neurohormonal activity have been shown to activate the coagulation system (17) (18) (19) (20) . The activation of the coagulation system and increased inflammation may cause consumptive coagulopathy. Moreover, systemic coagulation pathways are hyperactive or stimulated, and additional injury is a potent trigger resulting in markedly increased thrombin formation and platelet activation in ACS (21) . Thrombin itself has a proinflammatory effect in acute thromboembolic events (22) . Elevated levels of prothrombin fragment, which is a circulating thrombin marker, and thrombin-antithrombin complexes (TAT) triggered by vascular injury have been observed in ACS patients (23) (24) (25) (26) . Although TAT and prothrombin fragment levels were not measured in our study, there was a positive correlation between WBC count as an index of inflammation and PT. We believe that prolonged PT is related to inflammation, which contributes to the consumptive coagulopathy.
Since coagulation factors are synthesized in the liver, hepatic injury or failure may lead to a decrease in plasma coagulation factors. Alehagen et al. showed that coagulation factors such as II, VII, and XI can be decreased in heart failure patients (27) . That decrease was not related to the level of ALT, which is one of the most sensitive enzymes indicating liver disease in that study. In another study, an improvement in the factor II, V, VII, and IX levels was observed in heart failure patients after implantation of an LV assist device, regardless of hepatic dysfunction (e.g., ALT > 60 U/L) (28) . LVEF was lower in the high-PT group in the present study. On the other hand, total bilirubin, which is a nonspecific marker of liver damage, was positively and a weak correlated with PT in the current study. Thus, we believe that hepatic dysfunction is partially responsible for the prolongation of PT.
In a recent study, prolonged PT and an increased INR in the absence of anticoagulant therapy were associated with six-month mortality in patients with acute pulmonary embolism (8) . INR > 
1-Specificity
1.2 was independent predictor of mortality in those patients. Moreover, per 1-sec increase in PT on admission was related to mortality in those patients (8) . Fei et al. reported that PT was significantly more prolonged in non-survivors than in survivors who were hospitalized in an intensive care unit (29) . They also found that PT of 12 sec was a cut-point for predicting in-hospital mortality, with a sensitivity of 83% and a specificity of 51%.
Hannan et al. showed prolonged PT was independently associated with mortality in patients underwent coronary artery bypass grafting (CABG) (9) . In their study, patients with PT ≥ 14 sec had a 1.86 fold increased risk of 30-day mortality in these patients. Tamayo et al. revealed that there was a relationship between high INR and 90-day mortality in Post Cardiac Surgery (POCAS) Scale in patients who were treated with CABG (30) . In a prospective, multicenter observational cohort study, it was observed that, of the 1,923 patients admitted to the ICU, 30% developed abnormal INR values (defined as an INR > 1.5) (31) . Most of the INR abnormalities were minor and short-lived (73% of the worst INR values 1.6 to 2.5). In all the regression models, there was a strong independent association between abnormal INR values and greater ICU mortality (p< 0.0001), particularly when the INR increased after ICU admission (31) . Similar to the above-mentioned studies, prolonged PT in the absence of anticoagulant therapy was independently associated with longterm mortality in ACS patients underwent PCI in our study.
Acute traumatic coagulopathy (ATC), as defined by an elevated INR, is a well-studied and increasingly welldefined entity in adults after injury, and it was associated with mortality (32) (33) (34) (35) . Coagulopathy was also identified as an independent risk factor for acute renal failure and multiorgan failure (36) . PT was found to be the independent predictor of long-term mortality in patients undergoing carotid stenting (37) . In that study, PT remained a significant predictor for mortality after excluding patients with (stopped) oral anticoagulation. We demonstrated the association of PT with mortality by also performing landmark analysis in present study. Moreover, we found that high-PT group had a lower survival rate even after the first 30-day. Although increased PT is treated with fresh frozen plasma, it is unclear whether the long-term risk associated with increased PT may be modified by treatment. It has been shown that there was not an association of transfusion with correction of PT/INR or improved survival (38) . Furthermore, studies in both adults and children showed that plasma transfusions to correction for mildly higher PT/INR routinely fail to normalize this value and expose patients to unnecessary risk and delays (39) (40) (41) . The major bleeding rates were similar between the groups in the present study. In addition, none of patients in our study received fresh frozen plasma. An elevated INR/PT may likely serve as a marker of systemic coagulation and inflammatory dysregulation rather than as a treatment target (38) .
In the light of these findings, we speculate that prolonged PT is a result of underlying patient comorbidities (e.g., hepatic dysfunction, heart failure, DM, stroke/TIA). Moreover, it may be a marker of severity of ACS (e.g., higher Killip class). It may also reflect hemostatic imbalance and systemic inflammation.
Study Limitations
Our study has several limitations. First, it is a retrospective and non-randomized study. Thus, it is likely subject to selection bias. However, we were careful to enroll consecutive patients. We did not routinely measure commonly used inflammatory markers such as C-reactive protein and interleukins. Thus, PT was not compared with these inflammatory markers. Moreover, we did not measure the level of specific coagulation factors such as factor II, VII, and IX in these patients.
CONCLUSION
Our findings suggest that prolonged initial PT in the absence of anticoagulant use may be an independent predictor of all-cause mortality in ACS patients undergoing PCI. It may be associated with inflammation, lower EF, and hepatic insufficiency. Furthermore, ACS patients with prolonged PT may require close care for clinical events such as death and heart failure at followup. Large prospective studies are required to evaluate the exact prognostic impact of PT in these patients.
